Cancer immunotherapy by intratumoral injection of α-gal glycolipids

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3861-3868

  Whalen, Giles F ^a   Sullivan, Mary ^a   Piperdi, Bilal ^a   Wasseff, Wahid ^a   Galili, Uri ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

gal glycolipids; Anti Gal antibody; Autologous tumor antigens; Cancer immunotherapy

Indexed keywords

ALPHA GAL GLYCOLIPID; ALPHA GAL GLYCOLIPID ANTIBODY; ANTIBODY; ANTINEOPLASTIC AGENT; CANCER VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIBODY BLOOD LEVEL; ANTIGEN PRESENTING CELL; APPENDIX CARCINOMA; ARTICLE; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; AUTOANTIBODIES; BREAST NEOPLASMS; CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRALESIONAL; MALE; MCF-7 CELLS; MIDDLE AGED; NEOPLASMS; TRISACCHARIDES;

EID: 84867009699     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. thor Straten P, Becker JC, Guldberg P and Zeuthen J: In situ T cells in melanoma, Cancer Immunol Immunother 48: 386-395, 1999.
2. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl J Med 348: 203-213, 2003. (Pubitemid 36077915)
3. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Pagès F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006. (Pubitemid 44498003)
4. Galon J, Fridman WH and Pagès F: The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67: 1883-1886, 2007. (Pubitemid 46424201)
5. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F and Galon J: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Onco 29: 610-618, 2011.
6. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-999, 2002.
7. Khong HT and Restifo NP: Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3: 999-1005, 2002. (Pubitemid 35363649)
8. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE and Vogelstein B: The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113, 2007. (Pubitemid 350134889)
9. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES and Meyerson M: Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898, 2007. (Pubitemid 350231325)
10. Mumberg D, Wick M and Schreiber H: Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol 8: 289-293, 1996. (Pubitemid 26413869)
11. Galili U: Autologous tumor vaccines processed to express α-gal epitopes: A practical approach to immunotherapy in cancer. Cancer Immunol Immunother 53: 935-945, 2004.
12. Schmidt W, Schweighoffer T, Herbst E, Maass G, Berger M, Schilcher F, Schaffner G and Birnstiel ML: Primaring of tumor-specific T cells in the draining lymph nodes after immunization with interleukin-2 secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 92: 5540-5544, 1995.
13. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kündig T and Hengartner H: Antigen localization regulates immune responses in a dose and time dependent fashion: A geographical view of immune reactivity. Immunol Rev 156: 199-211, 1997.
14. Finn OJ: Cancer Immunology. New Engl J Med 358: 2704-2015, 2008.
15. Smyth MJ, Godfrey DI and Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2: 293-299, 2001. (Pubitemid 33706339)
16. Manches O, Plumas J, Lui G, Chaperot L, Molens JP, Sotto JJ, Bensa JC and Galili U: Anti-Gal mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy with autologous tumor cells. Haematologica 90: 625-634, 2005. (Pubitemid 40780881)
17. Galili U, Wigglesworth K and Abdel-Motal UM: Intratumoral injection α-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol 178: 4676-4687, 2007. (Pubitemid 46501667)
18. Abdel-Motal UM, Wigglesworth K and Galili U: Intratumoral injection α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother 58: 1545-1556, 2009.
19. Galili U, Rachmilewitz EA, Peleg A and Flechner I: A unique natural human IgG antibody with antα-galactosyl specificity. J Exp Med 160: 1519-1531, 1984. (Pubitemid 15220780)
20. Galili U, Macher BA, Buehler JS and Shohet SB: Human natural anti-α-galactosyl IgG. II. The specific recognition α (1,3)-linked galactose residues. J Exp Med 16: 573-582, 1985. (Pubitemid 15249960)
21. Galili U, Clark MR, Shohet SB, Buehler J and Macher BA: Evolutionary relationship between the anti-Gal antibody and the Galα1-3Gal epitope in primates. Proc Natl Acad Sci USA 84: 1369-1373, 1987. (Pubitemid 17027355)
22. Galili U, Shohet SB, Kobrin E, Stults CL and Macher BA: Man, apes, and Old World monkeys differ from other mammals in the expression α-galactosyl epitopes on nucleated cells. J Biol Chem 263: 17755-17762, 1988.
23. Macher BA and Galili U: The Galα,3Galß1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochem Biophys Acta 1780: 75-88, 2008.
24. Galili U: Interaction of the natural anti-Gal antibody wit α-galactosyl epitopes: a major obstacle for xenotranplantation in humans. Immunol Today 14: 480-482, 1993.
25. Good AH, Cooper DK, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N and Lamontagne LR: Identification of carbohydrate structures which bind human anti-porcine antibodies: implication for discordant xenografting in man. Transplant Proc 24: 559-562, 1992.
26. Sandrin M, Vaughan HA, Dabkowski PL and McKenzie IF: Anti-pig IgM antibodies in human serum react predominantly with Galα1-3Gal epitopes. Proc Natl Acad Sci USA 90: 11391-11395, 1993. (Pubitemid 23354435)
27. Collins BH, Cotterell HA, McCurry KR, Alvarado CG, Magee JC, Parker W and Platt JL: Cardiac xenografts between primate species provide evidence of the α-galactosyl determinant in hyperacute rejection. J Immunol 154: 5500-5510, 1995.
28. Galili U, LaTemple DC and Radic MZ: A sensitive assay for measurin α-gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation 65: 1129-1132, 1998. (Pubitemid 28208434)
29. Stone KR, Abdel-Motal U, Walgenbach AW, Turek TJ and Galili U: Replacement of human anterior cruciate ligament with pig ligament: a model for anti-non gal antibody response in long-term xenotransplantation. Transplantation 83: 211-219, 2007. (Pubitemid 46185212)
30. Callahan MK, Wolchok JD and Allison JP: Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 37: 473-484, 2010.
31. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A and Wolchok JD: Ipilimumab plus carbamazide for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2010.